Is Spironolactone for Acne? How It Works and Who Benefits

Spironolactone is widely prescribed for acne in women, even though it was never designed for that purpose. Originally developed in the 1950s as a blood pressure and heart failure drug, spironolactone’s ability to block androgen hormones turned out to be remarkably useful for treating hormonal breakouts. It remains an off-label use, meaning no regulatory agency has formally approved it specifically for acne, but decades of clinical experience and a growing body of trial data have made it one of the most commonly recommended options for adult women whose acne persists despite standard treatments.

How Spironolactone Fights Acne

Acne in adult women is frequently driven by androgens, the group of hormones that includes testosterone and its more potent derivative, dihydrotestosterone (DHT). These hormones ramp up oil production in the skin and can make pores more likely to clog. Spironolactone works by competing with DHT for binding spots on androgen receptors, effectively blocking the hormone’s signal from reaching oil glands and hair follicles. It also interferes with enzymes involved in making androgens in the first place.

This two-pronged action is why spironolactone can be effective even in women whose blood androgen levels test within the normal range. The drug doesn’t just lower circulating hormone levels; it blocks their effects at the tissue level. That distinction matters because many women with hormonally driven acne have perfectly normal lab results but skin that is unusually sensitive to androgens.

What the Clinical Evidence Shows

The evidence base for spironolactone in acne has improved substantially in recent years, though it still has some gaps. A large placebo-controlled trial in England and Wales, known as the SAFA trial, found that women taking 150 mg of spironolactone daily reported significantly better acne-related quality of life than those on placebo by week 24. About 82% of the spironolactone group reported improvement compared with 63% on placebo, and treatment success as rated by investigators was roughly three times more likely in the spironolactone group at the 12-week mark.¹ One interesting pattern from this trial: the difference between spironolactone and placebo was modest at 12 weeks but widened considerably by 24 weeks, reinforcing that this is not a quick fix.

A retrospective study of 110 women found even more encouraging numbers. About 85% experienced some reduction in acne scores while on spironolactone, and roughly 55% became completely clear across the face, chest, and back. The average reduction in acne severity was around 73–78% depending on body area.² A 2025 meta-analysis pooling data from seven randomized trials found that spironolactone significantly reduced acne severity scores compared to placebo and had a satisfactory safety profile.³

That said, a systematic review noted that many of the older trials were small and had methodological limitations, and the overall quality of evidence was rated low for most outcomes.⁴ The SAFA trial addressed many of those earlier weaknesses, but dermatologists still rely heavily on clinical experience alongside the trial data when prescribing spironolactone for acne.

How It Compares to Other Acne Treatments

One question that comes up constantly is how spironolactone stacks up against the oral antibiotics that doctors have traditionally prescribed for moderate acne. A multicenter, double-blind trial directly comparing spironolactone with doxycycline in adult women found that spironolactone performed better at the four-month mark and was nearly three times more successful than doxycycline after six months. Women on spironolactone also reported better quality of life and tolerated the drug well.⁵

This comparison is meaningful for a practical reason beyond raw effectiveness. Oral antibiotics carry concerns about antibiotic resistance when used for months at a time, a growing public health issue. Spironolactone sidesteps that problem entirely because it isn’t an antibiotic. The SAFA trial’s health-economic analysis also found that spironolactone was cost-effective compared with oral antibiotics, with an incremental cost of roughly £2,700 per quality-adjusted life year gained.⁶

Current expert recommendations suggest spironolactone should be especially considered in women who haven’t responded to a three-month course of oral antibiotics, those who relapsed after antibiotics were stopped, and women whose acne returned after isotretinoin. It can also serve as first-line systemic therapy for women whose acne pattern suggests a hormonal driver.⁷

Who Benefits Most

Spironolactone works best for a fairly specific profile: adult women with acne concentrated along the lower face, jawline, and chin, often flaring around the menstrual cycle. This distribution pattern is a hallmark of hormonally influenced breakouts. Teenagers with acne driven mainly by the T-zone and forehead may get less benefit because their acne tends to be driven more by puberty-related oil production than by the androgen sensitivity that spironolactone targets.

Women with polycystic ovary syndrome (PCOS) represent another group that often responds well. A study of PCOS patients found that spironolactone significantly reduced signs of excess androgen activity in both lean and overweight women, and acne improved in the majority of those who had it at baseline.⁸ Because PCOS involves elevated androgen activity, spironolactone addresses a root cause rather than just managing symptoms on the surface.

Spironolactone is not prescribed for men with acne. Its anti-androgen effects would cause feminizing side effects including breast tissue growth and decreased libido, making it inappropriate for male patients. This is one of the clearest limitations of the drug and means that it occupies a niche specifically in female dermatology.

Dosage and How Long It Takes to Work

Most dermatologists start at 50 to 100 mg daily and may increase to 150 or 200 mg depending on the response. In the retrospective study of 110 women, the majority began on 100 mg daily. Among those who started at that dose, 85 showed initial improvement and 40 became completely clear.² The SAFA trial used 150 mg daily and found significant benefits by 24 weeks.¹

Patience is essential. The onset of action for spironolactone is slower than many other acne treatments, generally around 12 weeks, with a typical range of 8 to 20 weeks before clear improvement.⁹ Some women notice changes within a month or two, but the full effect usually takes longer. This is a common reason people give up on the drug too early, expecting the kind of rapid response they might see with a course of antibiotics. The flip side is that benefits tend to persist for at least a month after stopping the medication, which isn’t something antibiotics typically offer.

Side Effects in Practice

Because spironolactone was designed as a diuretic, increased urination is one of the first things people notice, especially in the first few weeks. That effect usually settles down. The more significant side effects relate to its hormonal activity. In the 110-patient retrospective study, 34 women experienced menstrual irregularities, with breakthrough bleeding or spotting being the most common complaint. Non-menstrual side effects affected 26 women and included increased urinary frequency, drowsiness, and fatigue.¹⁰ The SAFA trial found that headaches were somewhat more common in the spironolactone group, with about 20% reporting them compared to 12% on placebo, though no serious adverse reactions occurred.¹

Breast tenderness is another frequently mentioned side effect. Many women find these issues mild enough to tolerate, especially once they see their skin improving. Taking the medication with food and staying hydrated can help with dizziness and the diuretic effect. For women already on oral contraceptives, the menstrual irregularities tend to be less of a concern because the pill regulates the cycle independently.

The Potassium Monitoring Debate

Spironolactone is classified as a potassium-sparing diuretic, which means it can theoretically cause potassium levels to rise too high, a condition called hyperkalemia. When the drug is used in heart failure patients, who are often elderly and on multiple medications that also affect potassium, regular blood monitoring is standard and important. But when healthy young women take it for acne, the picture looks very different.

A study analyzing over 1,800 potassium measurements in young women taking spironolactone for acne found that the rate of elevated potassium was 0.72%, essentially identical to the 0.76% baseline rate in this population. Six of the 13 abnormal readings normalized on repeat testing, suggesting they were lab errors, and no clinical action was needed in any case. The researchers concluded that routine potassium monitoring is unnecessary for healthy young women on spironolactone for acne.¹¹ A separate retrospective study from the RADAR program reached the same conclusion, finding that hyperkalemia rarely occurs in otherwise healthy women under 46.¹²

Despite this evidence, many providers still order potassium checks before starting the drug and periodically thereafter. The practice reflects older protocols designed for cardiac patients rather than the current data on young women using it for skin conditions. If your doctor skips the blood work and you’re a healthy woman under 45 with no kidney problems, that decision is well supported by the research. If you have kidney disease, take potassium supplements, or use other medications that raise potassium (like certain blood pressure drugs), monitoring still makes sense.

A randomized trial using a lower dose of spironolactone combined with topical benzoyl peroxide also found no significant changes in serum potassium or creatinine levels during treatment.¹³

The Breast Cancer Question

Because spironolactone has anti-androgen and mildly pro-estrogenic effects, a longstanding concern has been whether it might increase the risk of hormone-sensitive cancers, particularly breast cancer. This worry traces back to early animal studies using extremely high doses. The human evidence tells a different story.

A large retrospective cohort study of women older than 55 taking spironolactone for cardiovascular conditions found no evidence of increased breast cancer risk. The hazard ratio was essentially 1.0, meaning users and non-users developed breast cancer at the same rate.¹⁴ An even larger study following 2.3 million women did observe slightly elevated cancer rates in the first year of spironolactone use, but the same pattern appeared with furosemide (a completely unrelated diuretic), and the increases were not specific to estrogen-sensitive cancers. The researchers attributed this to reverse causality: women being treated for symptoms that turned out to be caused by an undiagnosed cancer. For drug exposure beginning more than a year before any cancer diagnosis, there was no increased risk of breast, uterine, ovarian, or cervical cancer.¹⁵

These findings are reassuring, particularly for the younger women who typically use spironolactone for acne and may take it for years. The breast cancer concern is one of the most common reasons women hesitate to try the drug, and the data consistently show it to be unfounded.

Pregnancy and Contraception

Spironolactone is categorized as unsafe during pregnancy. Its anti-androgen mechanism means it could interfere with the normal development of a male fetus, potentially causing feminization of the genitalia.¹⁶ For this reason, reliable contraception is considered essential for any woman of childbearing potential who takes the drug. Many dermatologists prescribe spironolactone alongside oral contraceptives, which serve the dual purpose of preventing pregnancy and providing additional acne benefit through their own hormonal effects.

If you’re actively trying to conceive or think you might become pregnant in the near term, spironolactone should be stopped. The drug clears the body relatively quickly, so planning ahead with your prescriber allows for a safe transition. There’s no evidence that prior use of spironolactone affects future fertility.

What Happens When You Stop

One common worry is whether acne will come roaring back the moment spironolactone is discontinued. The answer depends partly on the underlying hormonal driver. A study tracking women after stopping spironolactone found that about two-thirds maintained their improvement for an average of nearly 34 months after discontinuation. The remaining third relapsed, on average about 17 and a half months after stopping.¹⁷ Women with the classic form of PCOS tended to maintain benefits longer compared to those with milder ovulatory forms.

This suggests that for some women, spironolactone may need to be a long-term treatment, while for others, a course lasting a year or two might produce effects that stick. The decision about when and whether to stop usually involves a trial taper, gradually reducing the dose and watching for any return of breakouts.

Topical Spironolactone

The appeal of a topical version of spironolactone is obvious: you’d get the anti-androgen effect on the skin without the systemic side effects. Research on topical formulations exists but remains limited. One randomized controlled trial found that a 5% spironolactone gel reduced total lesion counts compared to placebo, though it didn’t significantly improve the acne severity index.¹⁸ A small pilot study of a 5% cream showed some promise but acknowledged its own limitations, including a lack of control group and short follow-up period.¹⁹

Topical spironolactone for acne is not yet widely available through mainstream dermatology channels, though some compounding pharmacies prepare it. It’s worth distinguishing this from topical clascoterone, a different anti-androgen cream that has received regulatory approval for acne. Clascoterone works through a similar receptor-blocking mechanism but was specifically developed and tested for topical use. If the idea of a topical anti-androgen appeals to you but oral spironolactone feels like too much, clascoterone is the option with stronger regulatory backing, though it tends to be more expensive and is approved for milder acne.

Off-Label but Mainstream

The fact that spironolactone remains officially “off-label” for acne sometimes gives patients pause, but this label can be misleading. Off-label prescribing simply means a drug is being used for a condition other than the one it was originally approved for. It’s extremely common across all areas of medicine and isn’t a sign that a drug is experimental or unproven. Spironolactone has been used for acne since the 1980s, and its off-label status mostly reflects the economics of drug approval: because the patent expired decades ago, no pharmaceutical company has financial incentive to fund the large-scale trials that regulatory agencies require for a new indication. The growing body of clinical trial data, including the SAFA trial, has made the evidence base considerably stronger than what exists for many other off-label dermatological prescriptions.

1
The BMJ. Effectiveness of spironolactone for women with acne vulgaris (SAFA) in England and Wales: pragmatic, multicentre, phase 3, double blind, randomised controlled trial
2
Elsevier / International Journal of Women’s Dermatology. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients
3
PubMed. Oral and topical spironolactone in acne treatment: A meta-analysis of effectiveness and safety
4
PubMed Central. Oral Spironolactone for Acne Vulgaris in Adult Females: A Hybrid Systematic Review
5
PubMed Central. Efficacy of Spironolactone Compared with Doxycycline in Moderate Acne in Adult Females: Results of the Multicentre, Controlled, Randomized, Double-blind Prospective and Parallel Female Acne Spironolactone vs doxyCycline Efficacy (FASCE) Study
6
PubMed Central. Clinical and cost-effectiveness of spironolactone in treating persistent facial acne in women: SAFA double-blinded RCT
7
JAAD Reviews. Oral spironolactone for acne vulgaris in females: Evidence review and practical recommendations
8
PubMed Central. Efficacy of Spironolactone in Adult Acne in Polycystic Ovary Syndrome Patients an Original Research
9
PLoS ONE. The efficacy of Topical Clascoterone versus systematic spironolactone for treatment of acne vulgaris: A systematic review and network meta-analysis
10
Elsevier / International Journal of Women’s Dermatology. Spironolactone for the treatment of acne in women, a retrospective study of 110 patients
11
PubMed. Low Usefulness of Potassium Monitoring Among Healthy Young Women Taking Spironolactone for Acne
12
PubMed Central. Hyperkalemia in women with acne exposed to oral spironolactone: A retrospective study from the RADAR program
13
PubMed. Efficacy and tolerability of low-dose spironolactone and topical benzoyl peroxide in adult female acne: A randomized, double-blind, placebo-controlled trial
14
BMJ. Spironolactone and risk of incident breast cancer in women older than 55 years: retrospective, matched cohort study
15
Cancer Epidemiology. Spironolactone use and the risk of breast and gynecologic cancers
16
PubMed Central. Case report: A pregnant woman accidental treated with spironolactone in mid-estation
17
PubMed. Long-Lasting Effects of Spironolactone after its Withdrawal in Patients with Hyperandrogenic Skin Disorders
18
PubMed. Comparison of the efficacy of 5% topical spironolactone gel and placebo in the treatment of mild and moderate acne vulgaris: a randomized controlled trial
19
PubMed Central. Efficacy and safety of topical spironolactone 5% cream in the treatment of acne: A pilot study